Transcription factor Sp1, also known as specificity protein 1 as a therapeutic target

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 7, 2014, Pages 759-769

  Safe, Stephen ^a   Imanirad, Parisa ^a   Sreevalsan, Sandeep ^a   Nair, Vijayalekshmi ^a   Jutooru, Indira ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Antineoplastic agents; Kruppel like factor family; Specificity protein transcription factors; Targeted therapy

Indexed keywords

ACETYLSALICYLIC ACID; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CYCLOOXYGENASE 2 INHIBITOR; METFORMIN; MITHRAMYCIN; NATURAL PRODUCT; NONSTEROID ANTIINFLAMMATORY AGENT; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; TRANSCRIPTION FACTOR SP4;

CANCER CELL CULTURE; CANCER PATIENT; CANCER PROGNOSIS; DNA BINDING; DOWN REGULATION; DRUG INHIBITION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; GENE CONTROL; HUMAN; NONHUMAN; PROTEIN EXPRESSION; REVIEW; ANIMAL; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DOWN-REGULATION; HUMANS; NEOPLASMS; SP1 TRANSCRIPTION FACTOR;

EID: 84902472333     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.914173     Document Type: Review

References (107)

1. Black AR, Black JD, Azizkhan-Clifford J. Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 2001;188(2):143-60
2. Suske G, Bruford E, Philipsen S. Mammalian SP/KLF transcription factors: bring in the family. Genomics 2005;85(5):551-6
3. Safe S, Abdelrahim M. Sp transcription factor family and its role in cancer. Eur J Cancer 2005;41(16):2438-48
4. Wierstra I. Sp1: emerging roles-beyond constitutive activation of TATA-less housekeeping genes. Biochem Biophys Res Commun 2008;372(1):1-13
5. Marin M, Karis A, Visser P, et al. Transcription factor Sp1 is essential for early embryonic development but dispensable for cell growth and differentiation. Cell 1997;89(4):619-28
6. Gollner H, Bouwman P, Mangold M, et al. Complex phenotype of mice homozygous for a null mutation in the Sp4 transcription factor gene. Genes Cells 2001;6(8):689-97
7. Supp DM, Witte DP, Branford WW, et al. Sp4, a member of the Sp1-family of zinc finger transcription factors, is required for normal murine growth, viability, and male fertility. Dev Biol 1996;176(2):284-99
8. Nguyen-Tran VT, Kubalak SW, Minamisawa S, et al. A novel genetic pathway for sudden cardiac death via defects in the transition between ventricular and conduction system cell lineages. Cell 2000;102(5):671-82
9. Harrison SM, Houzelstein D, Dunwoodie SL, et al. Sp5, a new member of the Sp1 family, is dynamically expressed during development and genetically interacts with Brachyury. Dev Biol 2000;227(2):358-72
10. Nakashima K, Zhou X, Kunkel G, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002;108(1):17-29
11. Gollner H, Dani C, Phillips B, et al. Impaired ossification in mice lacking the transcription factor Sp3. Mech Dev 2001;106(1-2):77-83
12. Bell SM, Schreiner CM, Waclaw RR, et al. Sp8 is crucial for limb outgrowth and neuropore closure. Proc Natl Acad Sci USA 2003;100(21):12195-200
13. Baur F, Nau K, Sadic D, et al. Specificity protein 2 (Sp2) is essential for mouse development and autonomous proliferation of mouse embryonic fibroblasts. PLoS One 2010;5(3):e9587
14. Hertveldt V, Louryan S, van Reeth T, et al. The development of several organs and appendages is impaired in mice lacking Sp6. Dev Dyn 2008;237(4):883-92
15. Ammendola R, Mesuraca M, Russo T, et al. Sp1 DNA binding efficiency is highly reduced in nuclear extracts from aged rat tissues. J Biol Chem 1992;267(25):17944-8
16. Adrian GS, Seto E, Fischbach KS, et al. YY1 and Sp1 transcription factors bind the human transferrin gene in an agerelated manner. J Gerontol A Biol Sci Med Sci 1996;51(1):B66-75
17. Oh JE, Han JA, Hwang ES. Downregulation of transcription factor, Sp1, during cellular senescence. Biochem Biophys Res Commun 2007;353(1):86-91
18. Chintharlapalli S, Papineni S, Ramaiah SK, et al. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res 2007;67(6):2816-23
19. Abdelrahim M, Baker CH, Abbruzzese JL, et al. Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res 2007;67(7):3286-94
20. Chadalapaka G, Jutooru I, Chintharlapalli S, et al. Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res 2008;68(13):5345-54
21. Mertens-Talcott SU, Chintharlapalli S, Li X, et al. The oncogenic microRNA- 27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res 2007;67(22):11001-11
22. Papineni S, Chintharlapalli S, Abdelrahim M, et al. Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis 2009;30(7):1193-201
23. Colon J, Basha MR, Madero-Visbal R, et al. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest New Drugs 2011;29(1):41-51
24. Chintharlapalli S, Papineni S, Abdelrahim M, et al. Oncogenic microRNA-27a is a target for anticancer agent methyl 2-cyano-3,11-dioxo- 18betaolean- 1,12-dien-30-oate in colon cancer cells. Int J Cancer 2009;125(8):1965-74
25. Chintharlapalli S, Papineni S, Lee SO, et al. Inhibition of pituitary tumortransforming gene-1 in thyroid cancer cells by drugs that decrease specificity proteins. Mol Carcinog 2011;50(9):655-67
26. Chadalapaka G, Jutooru I, Sreevalsan S, et al. Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors. Int J Cancer 2013;132(4):795-806
27. Fulciniti M, Amin S, Nanjappa P, et al. Significant biological role of sp1 transactivation in multiple myeloma. Clin Cancer Res 2011;17(20):6500-9
28. Kong LM, Liao CG, Chen L, et al. Promoter hypomethylation up-regulates CD147 expression through increasing Sp1 binding and associates with poor prognosis in human hepatocellular carcinoma. J Cell Mol Med 2011;15(6):1415-28
29. Guan H, Cai J, Zhang N, et al. Sp1 is upregulated in human glioma, promotes MMP-2-mediated cell invasion and predicts poor clinical outcome. Int J Cancer 2012;130(3):593-601
30. Takahashi M, Nakamura Y, Obama K, et al. Identification of SP5 as a downstream gene of the beta-catenin/Tcf pathway and its enhanced expression in human colon cancer. Int J Oncol 2005;27(6):1483-7
31. Chen Y, Guo Y, Ge X, et al. Elevated expression and potential roles of human Sp5, a member of Sp transcription factor family, in human cancers. Biochem Biophys Res Commun 2006;340(3):758-66
32. Phan D, Cheng CJ, Galfione M, et al. Identification of Sp2 as a transcriptional repressor of carcinoembryonic antigenrelated cell adhesion molecule 1 in tumorigenesis. Cancer Res 2004;64(9):3072-8
33. Kim TH, Chiera SL, Linder KE, et al. Overexpression of transcription factor sp2 inhibits epidermal differentiation and increases susceptibility to wound- and carcinogen-induced tumorigenesis. Cancer Res 2010;70(21):8507-16
34. Jiang NY, Woda BA, Banner BF, et al. Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2008;17(7):1648-52
35. Bedolla RG, Gong J, Prihoda TJ, et al. Predictive value of Sp1/Sp3/FLIP signature for prostate cancer recurrence. PLoS One 2012;7(9):13
36. Maurer GD, Leupold JH, Schewe DM, et al. Analysis of specific transcriptional regulators as early predictors of independent prognostic relevance in resected colorectal cancer. Clin Cancer Res 2007;13(4):1123-32
37. Wang L, Wei D, Huang S, et al. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 2003;9(17):6371-80
38. Yao JC, Wang L, Wei D, et al. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 2004;10(12 Pt 1):4109-17
39. Li C, Ma Y, Xue Y, et al. Molecular characterization and significance for prognosis of free gastric cancer cells in the peritoneal cavity. Hepatogastroenterology 2009;56(91-92):891-8
40. Zhang J, Zhu ZG, Ji J, et al. Transcription factor Sp1 expression in gastric cancer and its relationship to long-term prognosis. World J Gastroenterol 2005;11(15):2213-17
41. Wang F, Ma YL, Zhang P, et al. SP1 mediates the link between methylation of the tumour suppressor miR-149 and outcome in colorectal cancer. J Pathol 2013;229(1):12-24
42. Wright C, Angus B, Napier J, et al. Prognostic factors in breast cancer: immunohistochemical staining for SP1 and NCRC 11 related to survival, tumour epidermal growth factor receptor and oestrogen receptor status. J Pathol 1987;153(4):325-31
43. Hsu TI, Wang MC, Chen SY, et al. Sp1 expression regulates lung tumor progression. Oncogene 2012;31(35):3973-88
44. Lee HS, Park CK, Oh E, et al. Low SP1 expression differentially affects intestinal-type compared with diffusetype gastric adenocarcinoma. PLoS One 2013;8(2):20
45. Essafi-Benkhadir K, Grosso S, Puissant A, et al. Dual role of Sp3 transcription factor as an inducer of apoptosis and a marker of tumour aggressiveness. PLoS One 2009;4(2):e4478
46. Lou Z, OReilly S, Liang H, et al. Down-regulation of overexpressed sp1 protein in human fibrosarcoma cell lines inhibits tumor formation. Cancer Res 2005;65(3):1007-17
47. Torti D, Trusolino L. Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med 2011;3(11):623-36
48. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009;136(5):823-37
49. Banerjee S, Sangwan V, McGinn O, et al. Triptolide-induced cell death in pancreatic cancer is mediated by O-GlcNAc modification of transcription factor Sp1. J Biol Chem 2013;288(47):33927-38
50. Xu X, Hamhouyia F, Thomas SD, et al. Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides. J Biol Chem 2001;276(46):43221-30
51. Borgatti M, Lampronti I, Romanelli A, et al. Transcription factor decoy molecules based on a peptide nucleic acid (PNA)-DNA chimera mimicking Sp1 binding sites. J Biol Chem 2003;278(9):7500-9
52. Ishibashi H, Nakagawa K, Onimaru M, et al. Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor beta1, and tissue factor and also cell growth and invasion activities. Cancer Res 2000;60(22):6531-6
53. Chae YM, Park KK, Magae J, et al. Sp1-decoy oligodeoxynucleotide inhibits high glucose-induced mesangial cell proliferation. Biochem Biophys Res Commun 2004;319(2):550-5
54. Mansilla S, Portugal J. Sp1 transcription factor as a target for anthracyclines: effects on gene transcription. Biochimie 2008;90(7):976-87
55. Wu J, Ling X, Pan D, et al. Molecular mechanism of inhibition of survivin transcription by the GC-rich sequenceselective DNA binding antitumor agent, hedamycin: evidence of survivin downregulation associated with drug sensitivity. J Biol Chem 2005;280(10):9745-51
56. Martin B, Vaquero A, Priebe W, et al. Bisanthracycline WP631 inhibits basal and Sp1-activated transcription initiation in vitro. Nucleic Acids Res 1999;27(17):3402-9
57. Jia Z, Zhang J, Wei D, et al. Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A. Cancer Res 2007;67(10):4878-85
58. Jia Z, Gao Y, Wang L, et al. Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity. Cancer Res 2010;70(3):1111-19
59. Yuan P, Wang L, Wei D, et al. Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer. Cancer 2007;110(12):2682-90
60. Gao Y, Jia Z, Kong X, et al. Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Cancer Res 2011;71(15):5182-93
61. Drucker L, Uziel O, Tohami T, et al. Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma. Mol Pharmacol 2003;64(2):415-20
62. Safe SH, Prather PL, Brents LK, et al. Unifying mechanisms of action of the anticancer activities of triterpenoids and synthetic analogs. Anticancer Agents Med Chem 2012;12(10):1211-20
63. Abdelrahim M, Smith R III, Burghardt R, et al. Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res 2004;64(18):6740-9
64. Wei D, Wang L, He Y, et al. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 2004;64(6):2030-8
65. Abdelrahim M, Safe S. Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins. Mol Pharmacol 2005;68(2):317-29
66. Abdelrahim M, Baker CH, Abbruzzese JL, et al. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 2006;98(12):855-68
67. Konduri S, Colon J, Baker CH, et al. Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. Mol Cancer Ther 2009;8(3):533-42
68. Basha R, Baker CH, Sankpal UT, et al. Therapeutic applications of NSAIDS in cancer: special emphasis on tolfenamic acid. Front Biosci 2011;3:797-805
69. Maliakal P, Abdelrahim M, Sankpal UT, et al. Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats. Invest New Drugs 2012;30(3):853-61
70. Wilson H, Chadalapaka G, Jutooru I, et al. Effect of tolfenamic acid on canine cancer cell proliferation, specificity protein (sp) transcription factors, and spregulated proteins in canine osteosarcoma, mammary carcinoma, and melanoma cells. J Vet Intern Med 2012;26(4):977-86
71. Sankpal UT, Abdelrahim M, Connelly SF, et al. Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer. Prostate 2012;72(15):1648-58
72. Pathi SS, Jutooru I, Chadalapaka G, et al. GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species-microRNA- 27a: ZBTB10-specificity protein pathway. Mol Cancer Res 2011;9(2):195-202
73. Pathi S, Jutooru I, Chadalapaka G, et al. Aspirin inhibits colon cancer cell and tumor growth and downregulates specificity protein (Sp) transcription factors. PLoS One 2012;7(10):26
74. Bosetti C, Rosato V, Gallus S, et al. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 2012;23(6):1403-15
75. Fulda S, Kroemer G. Targeting mitochondrial apoptosis by betulinic acid in human cancers. Drug Discov Today 2009;14(17-18):885-90
76. Chintharlapalli S, Papineni S, Lei P, et al. Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors. BMC Cancer 2011;11(371):1471-2407
77. Chadalapaka G, Jutooru I, Burghardt R, et al. Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells. Mol Cancer Res 2010;8(5):739-50
78. Liu X, Jutooru I, Lei P, et al. Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a:ZBTB10 in breast cancer. Mol Cancer Ther 2012;11(7):1421-31
79. Mertens-Talcott SU, Noratto GD, Li X, et al. Betulinic acid decreases ER-negative breast cancer cell growth in vitro and in vivo: role of Sp transcription factors and microRNA-27a:ZBTB10. Mol Carcinog 2013;52(8):591-602
80. Hsu TI, Wang MC, Chen SY, et al. Betulinic acid decreases specificity protein 1 (Sp1) level via increasing the sumoylation of sp1 to inhibit lung cancer growth. Mol Pharmacol 2012;82(6):1115-28
81. Chadalapaka G, Jutooru I, Safe S. Celastrol decreases specificity proteins (Sp) and fibroblast growth factor receptor-3 (FGFR3) in bladder cancer cells. Carcinogenesis 2012;33(4):886-94
82. Kim K, Chadalapaka G, Pathi SS, et al. Induction of the transcriptional repressor ZBTB4 in prostate cancer cells by druginduced targeting of microRNA-17-92/ 106b-25 clusters. Mol Cancer Ther 2012;11(9):1852-62
83. Jutooru I, Chadalapaka G, Abdelrahim M, et al. Methyl 2-cyano- 3,12-dioxooleana-1,9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a. Mol Pharmacol 2010;78(2):226-36
84. Jutooru I, Chadalapaka G, Lei P, et al. Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation. J Biol Chem 2010;285(33):25332-44
85. Gandhy SU, Kim K, Larsen L, et al. Curcumin and synthetic analogs induce reactive oxygen species and decreases specificity protein (Sp) transcription factors by targeting microRNAs. BMC Cancer 2012;12(564):1471-2407
86. Noratto GD, Jutooru I, Safe S, et al. The drug resistance suppression induced by curcuminoids in colon cancer SW- 480 cells is mediated by reactive oxygen species-induced disruption of the microRNA-27a-ZBTB10-Sp axis. Mol Nutr Food Res 2013;57(9):1638-48
87. Yu J, Peng Y, Wu LC, et al. Curcumin down-regulates DNA methyltransferase 1 and plays an anti-leukemic role in acute myeloid leukemia. PLoS One 2013;8(2):13
88. Zheng L, Li D, Xiang X, et al. Methyl jasmonate abolishes the migration, invasion and angiogenesis of gastric cancer cells through down-regulation of matrix metalloproteinase 14. BMC Cancer 2013;13(74):1471-2407
89. Chae JI, Jeon YJ, Shim JH. Downregulation of Sp1 is involved in honokiol-induced cell cycle arrest and apoptosis in human malignant pleural mesothelioma cells. Oncol Rep 2013;29(6):2318-24
90. Lee KA, Chae JI, Shim JH. Natural diterpenes from coffee, cafestol and kahweol induce apoptosis through regulation of specificity protein 1 expression in human malignant pleural mesothelioma. J Biomed Sci 2012;19(60):1423-0127
91. Fang Y, Yu Y, Hou Q, et al. The Chinese herb isolate isorhapontigenin induces apoptosis in human cancer cells by down-regulating overexpression of antiapoptotic protein XIAP. J Biol Chem 2012;287(42):35234-43
92. Gupta SC, Kim JH, Prasad S, et al. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 2010;29(3):405-34
93. Chae JI, Cho JH, Lee KA, et al. Role of transcription factor Sp1 in the quercetinmediated inhibitory effect on human malignant pleural mesothelioma. Int J Mol Med 2012;30(4):835-41
94. Yu HJ, Shin JA, Nam JS, et al. Apoptotic effect of dibenzylideneacetone on oral cancer cells via modulation of specificity protein 1 and Bax. Oral Dis 2013;19(8):767-74
95. Lee KA, Lee YJ, Ban JO, et al. The flavonoid resveratrol suppresses growth of human malignant pleural mesothelioma cells through direct inhibition of specificity protein 1. Int J Mol Med 2012;30(1):21-7
96. Nair V, Pathi S, Jutooru I, et al. Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors. Carcinogenesis 2013;34(12):2870-9
97. Huang PH, Wang D, Chuang HC, et al. alpha-Tocopheryl succinate and derivatives mediate the transcriptional repression of androgen receptor in prostate cancer cells by targeting the PP2A-JNK-Sp1-signaling axis. Carcinogenesis 2009;30(7):1125-31
98. Wei S, Chuang HC, Tsai WC, et al. Thiazolidinediones mimic glucose starvation in facilitating Sp1 degradation through the up-regulation of betatransducin repeat-containing protein. Mol Pharmacol 2009;76(1):47-57
99. Sreevalsan S, Safe S. The cannabinoid WIN 55,212-2 decreases specificity protein transcription factors and the oncogenic cap protein eIF4E in colon cancer cells. Mol Cancer Ther 2013;12(11):2483-93
100. Chimienti F, Seve M, Richard S, et al. Role of cellular zinc in programmed cell death: temporal relationship between zinc depletion, activation of caspases, and cleavage of Sp family transcription factors. Biochem Pharmacol 2001;62(1):51-62
101. Rickers A, Peters N, Badock V, et al. Cleavage of transcription factor SP1 by caspases during anti-IgM-induced B-cell apoptosis. Eur J Biochem 1999;261(1):269-74
102. Tatsukawa H, Sano T, Fukaya Y, et al. Dual induction of caspase 3- and transglutaminase-dependent apoptosis by acyclic retinoid in hepatocellular carcinoma cells. Mol Cancer 2011;10(4):1476-4598
103. Piedrafita FJ, Pfahl M. Retinoid-induced apoptosis and Sp1 cleavage occur independently of transcription and require caspase activation. Mol Cell Biol 1997;17(11):6348-58
104. Wang YT, Yang WB, Chang WC, et al. Interplay of posttranslational modifications in Sp1 mediates Sp1 stability during cell cycle progression. J Mol Biol 2011;414(1):1-14
105. Ye X, Liu SF. Lipopolysaccharide causes Sp1 protein degradation by inducing a unique trypsin-like serine protease in rat lungs. Biochim Biophys Acta 2007;2:243-53
106. Tatsukawa H, Fukaya Y, Frampton G, et al. Role of transglutaminase 2 in liver injury via cross-linking and silencing of transcription factor Sp1. Gastroenterology 2009;136(5):1783-95
107. Kojima S, Kuo TF, Tatsukawa H, et al. Induction of cross-linking and silencing of Sp1 by transglutaminase during liver injury in ASH and NASH via different ER stress pathways. Dig Dis 2010;28(6):715-21